UNSPSC 51362306: Zolpidem hemitartrate

This classification denotes a sedative and hypnotic with the molecular formula 2C19H21N3O.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WY6W63843K, chemically known as imidazo(1,2-a)pyridine-3-acetamide, n,n,6-trimethyl-2-(4-methylphenyl)-, (r-(r*,r*))-2,3-dihydroxybutanedioate (2:1), but more generally known as zolpidem hemitartrate, which bears US NIH Compound Identifier 57487.

European Medicines Agency schedules zolpidem hemitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00183MIG. Most nations, for tariff purposes, schedule zolpidem hemitartrate under HS 29339990. SMILES: CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.CC1CCC(CC1)C2C(N3CC(CCC3N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51362306 Zolpidem hemitartrate is a Commodity code representing a specific pharmaceutical product, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity that diverges substantially from the code's nominal scope. The three most recent solicitations span naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission), and multi-state generic pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance). State and local buyers under this code include county health departments, state pharmacy and human services agencies, and cooperative purchasing organizations serving multiple jurisdictions. The work being solicited encompasses product procurement, wholesaler relationship management, pricing compliance, manufacturing certifications (cGMP and DSCSA), and supply-chain logistics tied to state Medicaid, employee group health plans, and community health initiatives.

Activity under the code spans Florida, Texas, Minnesota, and Oregon through recent solicitations. Seminole County released an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), requiring quarterly deliveries and electronic bid submission through the county e-Procurement Portal with two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program serving self-insured employee health plans and state agencies, functioning as exploratory market intelligence before a formal RFP. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative and technical compliance including EDI capability and cGMP/DSCSA certification.